JPWO2022075458A1 - - Google Patents

Info

Publication number
JPWO2022075458A1
JPWO2022075458A1 JP2022555596A JP2022555596A JPWO2022075458A1 JP WO2022075458 A1 JPWO2022075458 A1 JP WO2022075458A1 JP 2022555596 A JP2022555596 A JP 2022555596A JP 2022555596 A JP2022555596 A JP 2022555596A JP WO2022075458 A1 JPWO2022075458 A1 JP WO2022075458A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022555596A
Other languages
Japanese (ja)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2022075458A1 publication Critical patent/JPWO2022075458A1/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022555596A 2020-10-09 2021-10-08 Pending JPWO2022075458A1 (enExample)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020171491 2020-10-09
JP2020217698 2020-12-25
PCT/JP2021/037410 WO2022075458A1 (ja) 2020-10-09 2021-10-08 結核菌抽出物の新規用途

Publications (1)

Publication Number Publication Date
JPWO2022075458A1 true JPWO2022075458A1 (enExample) 2022-04-14

Family

ID=81126102

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022555596A Pending JPWO2022075458A1 (enExample) 2020-10-09 2021-10-08

Country Status (12)

Country Link
US (1) US20230372476A1 (enExample)
EP (1) EP4226939A4 (enExample)
JP (1) JPWO2022075458A1 (enExample)
KR (1) KR20230084177A (enExample)
CN (1) CN116322771A (enExample)
AU (1) AU2021357131A1 (enExample)
BR (1) BR112023006220A2 (enExample)
CA (1) CA3194869A1 (enExample)
MX (1) MX2023004103A (enExample)
TW (1) TW202228739A (enExample)
WO (1) WO2022075458A1 (enExample)
ZA (1) ZA202304219B (enExample)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS568320A (en) * 1979-07-04 1981-01-28 Chisato Maruyama Drug for tumor immunotherapy comprising lipopolysaccharide as active constituent
JPS5632489A (en) * 1979-08-28 1981-04-01 Mitsui Toatsu Chem Inc Antitumor active substance and its pharmaceutical
WO2005084708A1 (ja) * 2004-03-09 2005-09-15 Kyoto University Ｃｘｃｒ３阻害剤を含有する医薬組成物
JP2013129655A (ja) * 2011-11-25 2013-07-04 National Institute Of Advanced Industrial Science & Technology 免疫刺激因子担持微粒子
JP2014506576A (ja) * 2011-02-10 2014-03-17 ユニバーシティー オブ ルーイビル リサーチ ファンデーション，インコーポレーテッド ４−１ｂｂｌを含むアジュバント組成物
JP2019515005A (ja) * 2016-05-13 2019-06-06 四川大学 水酸化アルミニウムゲル−塩化ナトリウム複合免疫学的アジュバント、並びにその調製方法及びその使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0680574A (ja) * 1991-11-05 1994-03-22 Kiichiro Ozaki 間接的癌治療剤
US6274356B1 (en) * 1997-06-10 2001-08-14 Tai-Ho Chung Carbohydrate complex extracted from Mycobacterium tuberculosis and process for the preparation thereof
US7205404B1 (en) 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
GB0123756D0 (en) * 2001-10-03 2001-11-21 King S College London A novel chaperone-type of adjuvant for vaccination - Basic 1
JP4662925B2 (ja) * 2003-04-23 2011-03-30 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ 改善された効率を有する結核ワクチン
JP7367906B2 (ja) 2019-04-10 2023-10-24 株式会社 シコク 手摺装置
AU2020414040A1 (en) * 2019-12-27 2022-08-18 Zeria Pharmaceutical Co., Ltd. Cancer treatment method and medicine

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS568320A (en) * 1979-07-04 1981-01-28 Chisato Maruyama Drug for tumor immunotherapy comprising lipopolysaccharide as active constituent
JPS5632489A (en) * 1979-08-28 1981-04-01 Mitsui Toatsu Chem Inc Antitumor active substance and its pharmaceutical
WO2005084708A1 (ja) * 2004-03-09 2005-09-15 Kyoto University Ｃｘｃｒ３阻害剤を含有する医薬組成物
JP2014506576A (ja) * 2011-02-10 2014-03-17 ユニバーシティー オブ ルーイビル リサーチ ファンデーション，インコーポレーテッド ４−１ｂｂｌを含むアジュバント組成物
JP2013129655A (ja) * 2011-11-25 2013-07-04 National Institute Of Advanced Industrial Science & Technology 免疫刺激因子担持微粒子
JP2019515005A (ja) * 2016-05-13 2019-06-06 四川大学 水酸化アルミニウムゲル−塩化ナトリウム複合免疫学的アジュバント、並びにその調製方法及びその使用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HE JIN ET AL.: "Immune-adjuvant activity of lentinan-modified calcium carbonate microparticles on a H5N1 vaccine", INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, vol. 163, JPN6021044992, August 2020 (2020-08-01), pages 1384 - 1392, ISSN: 0005781175 *
SATO, H. ET AL.: "Antitumor activity of hot-water extract from delipidated BCG", THE TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, vol. 125, no. 3, JPN6021044994, 1978, pages 247 - 252, ISSN: 0005781174 *
YANG JUNBAO ET AL.: "Insights into Local Tumor Microenvironment Immune Factors Associated with Regression of Cutaneous Me", FRONTIERS IN ONCOLOGY, vol. 7, JPN6025039124, 2017, pages 61 - 1, ISSN: 0005781176 *

Also Published As

Publication number Publication date
EP4226939A4 (en) 2024-11-13
AU2021357131A1 (en) 2023-05-25
TW202228739A (zh) 2022-08-01
MX2023004103A (es) 2023-04-27
AU2021357131A9 (en) 2025-03-13
WO2022075458A1 (ja) 2022-04-14
KR20230084177A (ko) 2023-06-12
US20230372476A1 (en) 2023-11-23
ZA202304219B (en) 2023-12-20
CA3194869A1 (en) 2022-04-14
BR112023006220A2 (pt) 2023-05-09
CN116322771A (zh) 2023-06-23
EP4226939A1 (en) 2023-08-16

Similar Documents

Publication Publication Date Title
BR112023005462A2 (enExample)
BR112023012656A2 (enExample)
BR112021014123A2 (enExample)
BR112023009656A2 (enExample)
BR112022009896A2 (enExample)
BR112023008622A2 (enExample)
BR112022024743A2 (enExample)
BR112022026905A2 (enExample)
BR112021017747A2 (enExample)
BR112023011738A2 (enExample)
BR112023004146A2 (enExample)
BR112023006729A2 (enExample)
BR102021018859A2 (enExample)
BR102021015500A2 (enExample)
BR102021007058A2 (enExample)
BR102020022030A2 (enExample)
BR112023016292A2 (enExample)
BR112023011610A2 (enExample)
BR112023011539A2 (enExample)
BR112023008976A2 (enExample)
JPWO2022075458A1 (enExample)
BR102021020147A2 (enExample)
BR102021018926A2 (enExample)
BR102021018167A2 (enExample)
BR102021017576A2 (enExample)

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20230728

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230823

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260127